A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

Emily J Lelliott; Carleen Cullinane; Claire A Martin; Rachael Walker; Kelly M Ramsbottom; Fernando Souza-Fonseca-Guimaraes; Shatha Abuhammad; Jessica Michie; Laura Kirby; Richard J Young; Alison Slater; Peter Lau; Katrina Meeth; Jane Oliaro; Nicole Haynes; Grant A McArthur; Karen E Sheppard

Journal article

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

Emily J Lelliott, Carleen Cullinane, Claire A Martin, Rachael Walker, Kelly M Ramsbottom, Fernando Souza-Fonseca-Guimaraes, Shatha Abuhammad, Jessica Michie, Laura Kirby, Richard J Young, Alison Slater, Peter Lau, Katrina Meeth, Jane Oliaro, Nicole Haynes, Grant A McArthur, Karen E Sheppard

Scientific Reports | NATURE PUBLISHING GROUP | Published : 2019

DOI: 10.1038/s41598-018-37883-y

University of Melbourne Researchers

Grant McArthur Author Melbourne Medical School

Nicole Haynes Author The Sir Peter MacCallum Department of Oncology

Fernando Fonseca Guimaraes Author Medical Biology (W.E.H.I.)

Karen Sheppard Author The Sir Peter MacCallum Department of Oncology

Jane Oliaro Author The Sir Peter MacCallum Department of Oncology

Related Projects (1)

The Combination Of Cdk4 And Mapk/Erk Pathway Inhibitor Therapy In Melanoma: Defining Melanoma Cell Intrinsic And Immune Mediated Responses

Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments ..

Grants

Awarded by NHMRC of Australia

Awarded by Melbourne Research Scholarship (University of Melbourne)

Awarded by NHMRC Early Career Fellowship

Awarded by National Breast Cancer Foundation (NBCF) Fellowship

Awarded by NHMRC New Investigator Grant

Awarded by Priority-driven Collaborative Cancer Research Scheme

Funding Acknowledgements

This work was supported by grants from the NHMRC of Australia to GAM, KES, CC & NH (#1100189) and from Pfizer Oncology. EL was supported by a Peter MacCallum Cancer Centre Postgraduate Scholarship, Melbourne Research Scholarship (University of Melbourne; 58616) and a Cancer Therapeutics CRC (CTx) PhD Top Up Scholarship. FSFG was supported by a NHMRC Early Career Fellowship (1088703), a National Breast Cancer Foundation (NBCF) Fellowship (PF-15-008), a NHMRC New Investigator Grant (1140406), and a grant (1120725) awarded through the Priority-driven Collaborative Cancer Research Scheme and funded by Cure Cancer Australia with the assistance of Cancer Australia.